Texas Medical Center Innovation Factory’s Post

𝐀 𝐓𝐖𝐎 𝐁𝐄𝐀𝐑 𝐂𝐀𝐏𝐈𝐓𝐀𝐋 𝐏𝐎𝐑𝐓𝐅𝐎𝐋𝐈𝐎 𝐂𝐎𝐌𝐏𝐀𝐍𝐘: 𝐒𝐀𝐍𝐀𝐕𝐈𝐀 𝐎𝐍𝐂𝐎𝐋𝐎𝐆𝐘   Founded by Server Ertem, PhD, Sanavia Oncology Inc. believes that every cancer patient deserves a cure. For many patients drug resistance limits the benefit of current therapies. So Sanavia is working to access the biology that will provide the understanding needed to develop novel immunotherapies that can safely and effectively overcome drug resistance and improve patients’ lives. Sanavia uses a proprietary platform to discover unexplored, clinically relevant, cancer-specific epitopes in different types of drug resistant tumors and to generate antibodies with atomic-level specificity to these epitopes. Sanavia’s process combines high-throughput cellular analysis, single-molecule super-resolution microscopy, 3D protein modeling, and advanced computation to take maximum advantage of complementary 𝑖𝑛 𝑣𝑖𝑣𝑜 and 𝑖𝑛 𝑠𝑖𝑙𝑖𝑐𝑜 methods. Sanavia can replicate tumor biology ex-vivo with unprecedented accuracy and discover novel therapeutic targets at scale. For more information, visit www.sanavia.bio. #Sanavia #TwoBearCapital #VentureCapital #Oncology

In April, the Heidelberg Pharma AG team attended AACR in San Diego, where we presented promising first efficacy data on our lead clinical #ATAC product candidate, HDP-101, targeting relapsed and refractory multiple myeloma.   Our CMO, Andras Strassz, MD, MBA, spoke to Drug Discovery World´s Megan Thomas about his key takeaways from the conference and our goal of making #Amanitin available as a cancer therapy.   Check out Drug Discovery World's latest issue, linked here: https://lnkd.in/gtSZijU9   #ADCs #ATAC #ACR24 #CancerResearch

A recent study published in RSC Advances Journal used custom Simoa® assays to power important findings on the use of nanotechnologies in oncology. Harnessing Simoa's analytical sensitivity, these researchers developed a nanoSimoa pipeline, integrating Simoa with cancer nanomedicine. This new pipeline provided key insights into treatment effects on IL-6 and Ras signaling by accurately detecting protein level changes missed by conventional ELISA methods. With further validation, this pioneering approach using Simoa protein detection in nanomedicine evaluation could enhance preclinical testing predictiveness to accelerate preclinical testing. Explore the study and available and biomarker assays developed using homebrew in oncology research. 📄 https://bit.ly/3SdEnhg 🧪 https://bit.ly/3SafRh9 #nanomedicine #SimoaHomebrew #biomarkers #cancerresearch Royal Society of Chemistry

Exciting News: Our Latest Research Article is Out! I'm glad to share our recently published article titled "Marine-Derived Compounds for CDK5 Inhibition in Cancer: Integrating Multi-Stage Virtual Screening, MM/GBSA Analysis, and Molecular Dynamics Investigations." In this study, we explored the potential of marine-derived compounds in the fight against cancer by targeting CDK5, a critical protein. Our multi-stage approach combines virtual screening, MM/GBSA analysis, and molecular dynamics investigations to reveal promising leads. For those interested in cancer research, drug discovery, or computational biology, this article provides valuable insights into the world of marine chemistry and its applications in oncology. You can access the full article here: [https://lnkd.in/ej5aKVk4] Your thoughts, feedback, and shares are greatly appreciated. Let's continue pushing the boundaries of scientific knowledge together!

🔬 #Proteomics in #ClinicalOncology: Join us at our showcase evening in Paris – 'Next-Gen Proteomics for Advancing Translational and Clinical Oncology' on Jan 25th, 5-8 PM at Paris Saclay Cancer Cluster (PSCC), or online. Don't miss Genmab's Matthew Loya discussing 'Emerging Applications of Single FFPE Slide Proteomics in Clinical and Translational Research.' Matthew explores the potential of our #directDIA technology with FFPE tumor biopsies, offering high protein coverage even with single slides. With ~12,000 proteins detected, including key immuno-oncology targets, this breakthrough method promises efficient profiling for translational research and clinical trials. Join us to delve into the future of proteomics in oncology! 🌐👨🔬 👉 Register now on our website to secure your spot: https://ow.ly/5vzj50Qq1vs #Oncology #ClinicalResearch #DrugDiscovery #DrugDevelopment #Biomarkers

#InTheNews: EBC-129, the first made-in-Singapore antibody-drug conjugate to enter clinical development, has progressed into dose expansion 🙌 A recent update from the Experimental Drug Development Centre (EDDC) revealed that the first patient in the dose expansion study was dosed last 13 May 2024. A total of 45 patients across 3 groups are expected to participate in this stage. 🤝 This milestone is the product of years of collaboration between EDDC, the A*STAR Bioprocessing Technology Institute (BTI), Institute of Molecular and Cell Biology (IMCB) and the National Cancer Centre Singapore. For more on EDDC’s contributions as Singapore’s national platform for drug discovery and development, check out the articles linked below 👇 --- #scicomm #science #technology #STEM #research #innovation #ASTAR #HHP #EDDC #drugdevelopment #drugdiscovery #cancer #cancertherapeutics #oncology #throwback

I am pleased to announce the completion of my thesis titled "Nanocarriers for Targeted Drug Delivery in Cancer Treatment". This work explores innovative approaches to improve the precision of chemotherapy by utilizing nanotechnology to target tumor cells directly, reducing side effects and improving patient outcomes. Key findings demonstrate that specific nanocarrier designs can significantly optimize the delivery of therapeutic agents, providing new avenues for cancer treatment strategies. The collaboration with my advisors and peers has been instrumental in the success of this project. #CancerResearch #Nanotechnology #DrugDelivery #ThesisCompletion #Pharmacology

New research reveals that the presence of endotoxins in biomaterials can reduce the credibility of 3D in vitro cancer models. Read the EBR magazine article by Dr. Bjorn Vergauwen to find out why the use of purified biomaterials such as Rousselot’s X-Pure or X-Pure GelMA in in vitro 3D models is critical in producing a biologically relevant environment, while also helping to reduce the costs, time and ethical concerns associated with drug development. Read the full article here: https://hubs.ly/Q025LSNM0 #Biomedical #Biomaterials #Endotoxins #Gelatin #Immunotherapy #Oncology

Pioneering Medical Research with Terbium-161 🔬 Terbium-161 exhibits exciting potential as a radiopharmaceutical element. With its ability to emit beta radiation, it can precisely target cancer cells, providing prospects for more effective therapeutic solutions. Bellow is a scan we acquired using our benchtop modality, the γ-eye, on a healthy subject. We are excited to provide scientists with the tools they need. Embracing them translate ideas, into outcomes. #molecularimaging #research #terbium161 #theranostics

🔬 Excited to share our latest breakthrough in medicinal chemistry! 🎉 Our article, titled "A Potent Solution for Tumor Growth and Angiogenesis Suppression via ELR+CXCLCXCR1/2 Pathway Inhibitor," has been published in ACS Med Chem Letters. 💡 We're particularly thrilled to announce that our innovative work has been selected for the front cover of the journal! 📚 Our study explores a groundbreaking pathway inhibitor that shows promise in suppressing tumor growth and angiogenesis, paving the way for more effective cancer therapies. 🌟Congratulations to all authors: Grytsai, O., Dufies, M., Le Du, J., Rastoin, O., Pires Gonçalves, L. C., Mateo, L., Lacas-Gervais, S., Cao, Y., Demange, L., Pagès, G., Benhida, R., and Ronco, C. 🎉Check out the article to learn more about our groundbreaking approach and its potential impact on the field of medicine. #MedicinalChemistry #Innovation #Research #ACS #TargetedTherapies #ScienceCommunity